doxribtimine
Small moleculeapprovedOrphan Drug FDA
Approved
Nov 3, 2025
Clinical trial activity
2 trials · 2 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2025 (NCT06754098)
Timeline
Indications
Approved for
Studied for
Mechanism of action
- thymidineSupplementation
thymidine supplementation
Combination products
kygevvi
with doxecitine
Also known as doxecitine and doxribtimine
Approval history
- approvedPriority reviewNov 3, 2025
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O- Mol. weight
- 242.23 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL52609 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06754098 | Phase 2 | Jan 1, 2025 | UCB, Universidad Complutense de Madrid |
| NCT06590493 | N/A | — | UCB |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| UCB | For profit | 2 | 1 | 2 | 2025 |
| Universidad Complutense de Madrid | Academic/Hospital | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| UCB | For profit | NDA2 | Nov 3, 2025 |